2014 | 2017 | |||
---|---|---|---|---|
Country | Sweden | Norway | Sweden | Norway |
OAT studypopulation, n | 2663 | 6057 | 2739 | 5545 |
Gender, n (%) | ||||
Male | 1911 (72) | 4266 (70) | 1961 (72) | 3870 (70) |
Female | 752 (28) | 1791 (30) | 778 (28) | 1675 (30) |
Age, n (%) | ||||
18–35 | 671 (25) | 1219 (20) | 647 (24) | 878 (16) |
36–45 | 817 (31) | 2181 (36) | 819 (30) | 1747 (32) |
46–55 | 744 (28) | 2044 (34) | 713 (26) | 1998 (36) |
56–75 | 431 (16) | 613 (10) | 560 (20) | 922 (17) |
Mean age (SD) | ||||
Male | 44 (10) | 44.1 (9) | 45.1 (11) | 46.1 (9) |
Female | 43.5 (11) | 43.1 (9) | 44.3 (12) | 45.2 (10) |
OAT medication, n (%)a | ||||
Methadone/levomethadone | 1267 (48) | 2810 (46) | 1198 (44) | 2504 (45) |
Buprenorphine | 875 (33) | 2049 (34) | 1075 (39) | 2190 (40) |
Buprenorphine/naloxone | 521 (20) | 1198 (20) | 466 (17) | 851 (15) |